Deutsche Märkte schließen in 6 Stunden 48 Minuten

Amneal Pharmaceuticals, Inc. (2DT.F)

Frankfurt - Frankfurt Verzögerter Preis. Währung in EUR
Zur Watchlist hinzufügen
3,9130-0,0130 (-0,33%)
Ab 9:16AM MEZ. Markt geöffnet.

Amneal Pharmaceuticals, Inc.

400 Crossing Boulevard
3rd Floor
Bridgewater, NJ 08807
United States
908 947 3120
http://www.amneal.com

Sektor(en)Healthcare
BrancheDrug Manufacturers—Specialty & Generic
Vollzeitmitarbeiter5.500

Leitende Angestellte

NameTitelZahlenAusgeübtGeburtsjahr
Mr. Chirag K. PatelCo-Founder, Co-CEO, Pres & Director62,97kN/A1967
Mr. Chintu Patel R.Ph., R.PhCo-Founder, Co-CEO & Director64,6kN/A1972
Mr. Andrew S. BoyerExec. VP & Chief Commercial Officer of Generics675,09kN/A1966
Mr. Anastasios G. KonidarisExec. VP & CFON/AN/A1967
Mr. Stephen J. ManzanoSr. VP, Gen. Counsel & Corp. Sec.N/AN/A1965
Mr. James LuceExec. VP of Sales & MarketingN/AN/AN/A
Ms. Nikita ShahExec. VP and Chief HR Officer & Strategic Planning OfficerN/AN/A1978
Mr. Sanjiv PatelSr. VP of OperationsN/AN/AN/A
Ms. Candis EdwardsSr. VP of Regulatory AffairsN/AN/AN/A
Mr. Joseph Todisco MBAExec. VP & Chief Commercial Officer of SpecialtyN/AN/A1976
Die Beträge haben den Stand 31. Dezember 2019 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates in two segments, Generics and Specialty. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories. The Specialty segment is involved in the development, manufacture, and sale of branded pharmaceutical products primarily for central nervous system disorders, endocrinology, parasitic infections, and other therapeutic areas. It also offers licensed and owned, niche, and mature branded products, as well as Rytary for the treatment of Parkinsons Disease; Zomig for the treatment of migraine headaches; Emverm a chewable tablets for the treatment of pinworm, whipworm, common roundworm, common hookworm, and American hookworm in single or mixed infections; and Unithroid for the treatment of hypothyroidism. The company sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. It has operations in the United States, India, Ireland, and internationally. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is based in Bridgewater, New Jersey.

Corporate Governance

Amneal Pharmaceuticals, Inc.s ISS Governance QualityScore, Stand 1. Dezember 2020, lautet 6. Die grundlegenden Scores sind Audit: 2, Vorstand: 9, Shareholderrechte: 4, Kompensation: 3.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.